Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.

BrainsWay Ltd.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

THIS INVESTMENT MARKS BRAINSWAY'S ENTRANCE INTO THE MARKET FOR MENTAL HEALTH THERAPIES THAT CAN BE ADMINISTERED OUTSIDE OF A CLINIC, INCLUDING AT HOME

BRAINSWAY TARGETS EXPANSION OF ITS TOTAL ADDRESSABLE MARKET THROUGH A STRATEGIC INVESTMENT IN NEUROMODULATION SYSTEMS DEVELOPER, NEUROLIEF LTD.

THE INVESTMENT IS PART OF BRAINSWAY'S ONGOING STRATEGY TO ACQUIRE MINORITY POSITIONS IN LEADING U.S. MENTAL HEALTH PROVIDERS TO HELP THEM RAISE AWARENESS FOR AND EXPAND ACCESS TO TRANSFORMATIVE CARE THE INVESTMENT IS PART OF BRAINSWAY'S ONGOING STRATEGY TO ACQUIRE MINORITY POSITIONS IN LEADING U.S. MENTAL HEALTH PROVIDERS TO HELP THEM RAISE AWARENESS FOR AND EXPAND ACCESS TO TRANSFORMATIVE CARE

BRAINSWAY ACQUIRES MINORITY-STAKE IN AXIS INTEGRATED MENTAL HEALTH

ACHIEVED RECORD QUARTERLY REVENUE OF $12.6 MILLION IN Q2 2025, AN INCREASE OF 26% COMPARED TO Q2 2024 OPERATING PROFIT TOTALED $0.6 MILLION AND ADJUSTED EBITDA ROSE TO $1.5 MILLION, RAISED FULL-YEAR 2025 REVENUE AND EBITDA GUIDANCE REMAINING PERFORMANCE OBLIGATIONS INCREASED BY 25% YOY TO $62 MILLION CONFERENCE CALL TO BE HELD TODAY AT 8:30 AM ET BURLINGTON, MASS. AND JERUSALEM, AUG. 13, 2025 (GLOBE NEWSWIRE) -- BRAINSWAY LTD.

BRAINSWAY REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

IMPROVEMENT IN DEPRESSION SCORES, RESPONSE AND REMISSION WERE ALL FOUND TO BE COMPARABLE WITH STANDARD DEEP TMS IN NON-INFERIORITY TRIAL IMPROVEMENT IN DEPRESSION SCORES, RESPONSE AND REMISSION WERE ALL FOUND TO BE COMPARABLE WITH STANDARD DEEP TMS IN NON-INFERIORITY TRIAL

BRAINSWAY REPORTS POSITIVE RESULTS FROM MULTICENTER RANDOMIZED STUDY OF ACCELERATED DEEP TMS FOR MAJOR DEPRESSIVE DISORDER (MDD)

BURLINGTON, MASS. AND JERUSALEM, JUNE 10, 2025 (GLOBE NEWSWIRE) -- BRAINSWAY LTD.

BRAINSWAY ANNOUNCES GOLD SPONSORSHIP AT THE 2025 CLINICAL TMS SOCIETY ANNUAL MEETING IN SAN DIEGO

BRAINSWAY IS ACTIVELY EVALUATING SIMILAR INVESTMENTS IN OTHER LEADING U.S. MENTAL HEALTH PROVIDERS TO RAISE AWARENESS AND EXPAND ACCESS TO TRANSFORMATIVE CARE BRAINSWAY IS ACTIVELY EVALUATING SIMILAR INVESTMENTS IN OTHER LEADING U.S. MENTAL HEALTH PROVIDERS TO RAISE AWARENESS AND EXPAND ACCESS TO TRANSFORMATIVE CARE

BRAINSWAY ANNOUNCES $5 MILLION MINORITY-STAKE INVESTMENT IN STELLA MSO, LLC

ACHIEVED R ECORD QUARTERLY S ALES OF $11. 5 MILLION IN Q 1 202 5 , AN INCREASE OF 27% COMPARED TO Q 1 202 4

BRAINSWAY REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

ACHIEVED R ECORD QUARTERLY S ALES OF $11.4 MILLION IN Q4 2024 , AN INCREASE OF 27% COMPARED WITH Q4 2023

BRAINSWAY REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

BURLINGTON, MASS. AND JERUSALEM, DEC. 12, 2024 (GLOBE NEWSWIRE) -- BRAINSWAY LTD. (NASDAQ & TASE: BWAY) (BRAINSWAY OR THE COMPANY), A GLOBAL LEADER IN THE ADVANCED NON-INVASIVE TREATMENT OF BRAIN DISORDERS, TODAY ANNOUNCED RECENT POSITIVE PILOT DATA FROM AN INDEPENDENT, THIRD-PARTY STUDY CONDUCTED AT STANFORD UNIVERSITY EVALUATING AN ACCELERATED PROTOCOL USING THE COMPANY'S DEEP TRANSCRANIAL MAGNETIC STIMULATION (TMS) TECHNOLOGY TO TREAT ALCOHOL USE DISORDER (AUD) PATIENTS. THE OUTCOMES WERE REPORTED IN A PUBLICATION IN THE BRAIN STIMULATION JOURNAL ENTITLED, ACCELERATED DEEP TMS IN ALCOHOL USE DISORDER: A PRELIMINARY PILOT TRIAL TARGETING THE DORSAL ANTERIOR CINGULATE CORTEX INCREASES NEURAL TARGET ENGAGEMENT AND ABSTINENCE.

BRAINSWAY REPORTS POSITIVE INDEPENDENT PILOT DATA ON ACCELERATED DEEP TMS TREATMENT OF ALCOHOL USE DISORDER

BURLINGTON, MASS. AND JERUSALEM, ISRAEL, NOV. 20, 2024 (GLOBE NEWSWIRE) -- BRAINSWAY LTD.

BrainsWay Ltd.

BWAY

Price

Financials Overview

Financial Reports

No items found.

Press Releases

BrainsWay Ltd.

BWAY.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

BWAY